Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498185 | 0.90 | TSHR (0.49) | HPGDALDH1A1TSHRSMN1; SMN2APP | |
| SCHEMBL6500080 | 0.89 | CCR8 (0.50) | SMN1; SMN2APPKDM4EACHE | |
| SCHEMBL6498806 | 0.88 | ACHE (0.50) | MEN1KMT2AAPPKDM4EACHE | |
| SCHEMBL6496812 | 0.87 | BCHE (0.55) | KMT2ASMN1; SMN2APPPOLBACHE | |
| SCHEMBL6499418 | 0.86 | APP (0.46) | HCRTR2APPRAB9AACHE | |
| SCHEMBL6507435 | 0.85 | RAB9A (0.49) | HPGDMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6498983 | 0.84 | APP (0.49) | KMT2AAPPPOLBACHE | |
| SCHEMBL6508928 | 0.84 | GAA (0.62) | HPGDAPPPOLBKDM4EACHE | |
| SCHEMBL6500361 | 0.80 | APP (0.47) | APPACHE | |
| SCHEMBL6505243 | 0.80 | ACHE (0.51) | MEN1KMT2AAPPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | ATM 4854/4885HCRTR2 287/4885HPGD 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.